BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Moodys
Citi
Cerilliant
Covington
Merck
UBS
Teva
Argus Health
Julphar

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,070,808

« Back to Dashboard

Which drugs does patent 7,070,808 protect, and when does it expire?

Patent 7,070,808 protects EMSAM and is included in one NDA.

This patent has three patent family members in two countries.
Summary for Patent: 7,070,808
Title:Adhesive mixture for transdermal delivery of highly plasticizing drugs
Abstract:Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
Inventor(s): Govil; Sharad K. (Essex, VT), Weimann; Ludwig J. (Burlington, VT)
Assignee: Mylan Technologies, Inc. (St. Albans, VT)
Application Number:09/754,909
Patent Claim Types:
see list of patent claims
Formulation;

Drugs Protected by US Patent 7,070,808

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,070,808

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,150,881 Adhesive mixture for transdermal delivery of highly plasticizing drugs ➤ Subscribe
7,638,140 Adhesive mixture for transdermal delivery of highly plasticizing drugs ➤ Subscribe
8,846,093 Adhesive mixture for transdermal delivery of highly plasticizing drugs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Deloitte
AstraZeneca
Johnson and Johnson
Express Scripts
Chinese Patent Office
Medtronic
Covington
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot